ロード中...
Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma
Phase I testing of the hu14.18-IL2 immunocytokine (IC) in melanoma patients showed immune activation, reversible toxicities, and a maximal tolerated dose of 7.5 mg/m(2)/day. Preclinical data in IC-treated tumor-bearing mice with low tumor burden documented striking antitumor effects. Patients with c...
保存先:
| 出版年: | Cancer Immunol Immunother |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer Berlin Heidelberg
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6168354/ https://ncbi.nlm.nih.gov/pubmed/30073390 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-018-2223-z |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|